

HHS Public Access

Author manuscript *AIDS Care.* Author manuscript; available in PMC 2016 April 06.

Published in final edited form as:

AIDS Care. 2016 April; 28(4): 409-415. doi:10.1080/09540121.2015.1109587.

The relationship between adherence to clinic appointments and year-one mortality for newly enrolled HIV infected patients at a regional referral hospital in Western Kenya, January 2011– December 2012

Muthusi Kimeu^a, Barbara Burmen^b, Beryl Audi^b, Anne Adega^b, Karen Owuor^b, Susan Arodi^c, Dennis Bii^b, and Emily Zielinski-Gutiérrez^d

^aGlobal Programs for Research and Training, University of California, San Francisco, Nairobi, Kenya

^bHIV Implementation Science and Services Kenya Medical Research Institute/Centers for Global Health Research (KEMRI, CGHR), Kisumu, Kenya

^cHIV Comprehensive Care Centre, Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya

^dSurveillance and Epidemiology Branch, CDC Division of Global HIV AIDS, Kisumu, Kenya

Abstract

This retrospective cohort analysis was conducted to describe the association between adherence to clinic appointments and mortality, one year after enrollment into HIV care. We examined appointment-adherence for newly enrolled patients between January 2011 and December 2012 at a regional referral hospital in western Kenya. The outcomes of interest were patient default, risk factors for repeat default, and year-one risk of death. Of 582 enrolled patients, 258 (44%) were defaulters. GEE revealed that once having been defaulters, patients were significantly more likely to repeatedly default (OR 1.4; 95% CI 1.12–1.77), especially the unemployed (OR 1.43; 95% CI 1.07–1.91), smokers (OR 2.22; 95% CI 1.31–3.76), and those with no known disclosure (OR 2.17; 95% CI 1.42–3.3). Nineteen patients (3%) died during the follow-up period. Cox proportional hazards revealed that the risk of death was significantly higher among defaulters (HR 3.12; 95% CI 1.2–8.0) and increased proportionally to the rate of patient default; HR was 4.05 (95% CI 1.38–11.81) and 4.98 (95% CI 1.45–17.09) for a cumulative of 4–60 and 60 days elapsed between all scheduled and actual clinic appointment dates, respectively. Risk factors for repeat default suggest a need to deliver targeted adherence programs.

Disclosure statement

No potential conflict of interest was reported by the authors.

CONTACT Barbara Burmen, bburmen@kemricdc.org.

Authors contributions: Muthusi Kimeu took part in concept development, data management, and statistical analysis. Barbara Burmen took part in concept development, statistical analysis, and manuscript preparation and review. Beryl Audi, Anne Adega, Karen Owuor, Susan Arodi, and Dennis Bii took part in data collection and manuscript review. Emily Zielinski-Gutierrez provided technical oversight over manuscript writing, data analysis, and manuscript review.

Keywords

Compliance; HIV/AIDS; outcome; adherence; survival

HIV infection is an incurable illness that requires long-term engagement with health-care providers (Bofill, Waldrop-Valverde, Metsch, Pereyra, & Kolber, 2011; National AIDS and STI Control Program, 2011). Appointments at HIV Comprehensive Care Clinics (CCC) in Kenya are scheduled to coincide with prescription refills, adherence support, and timely delivery of required interventions (National AIDS and STI Control Program, 2011). Repeatedly missing appointments has been shown to lead to non-adherence to medication, faster disease progression, and treatment failure (Alamo et al., 2012; Fong, Cheng, Vujovic, & Hoy, 2013). Adherence to scheduled clinic visits can be used as an objective proxy for adherence to medication between clinic visits (National AIDS and STI Control Program, 2011; Park et al., 2007). We have examined the effect of adherence to clinic appointments on year-one mortality rates for newly diagnosed HIV-infected patients at a regional referral hospital in western Kenya.

Methods

Study design, setting, and population

A retrospective medical records review was conducted at the Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH), Kisumu, western Kenya for all patients aged 15 years (defined as adults by Kenya's HIV program) (Ministry of Health National AIDS and STI Control Program (NASCOP), 2014) enrolled between January 2011 and December 2012. Patients who transferred-in from other facilities were excluded.

Data collection

Clinicians entered data into structured forms during clinic visits per routine guidelines (Swash, 2001); forms were scanned and uploaded into clinic databases from which demographic, clinical (WHO stage and CD4 (Cluster of Differentiation 4) T cell counts), and psychosocial information (alcohol consumption, cigarette-smoking, and drug-abuse), clinic visits, and year-one patient outcomes were extracted. Patient disclosure status was described as "disclosed to family only" (reported disclosing positive HIV status to family member only), "disclosed to friends only" (reported disclosing to nonfamily), "disclosed to family and friends only" (disclosed to both family and non-family), "non-specific disclosure" (person disclosed to unidentified) or "no known disclosure" (no disclosure reported).

Scheduling of clinic appointments

At first clinical visit, all patients received a clinical assessment; baseline laboratory tests investigations, initiation of daily cotrimoxazole preventative therapy, appropriate treatment of opportunistic infections (OIs), and adherence counseling. Patients were scheduled to return two weeks later for review of test results and if ART eligible, initiated on ART within two weeks and provided preparatory adherence counseling. Patients were scheduled to return two weeks after ART initiation for initial ART monitoring. Patients were scheduled to

return monthly or quarterly for assessment of their physical condition, adherence assessment and counseling, and ART monitoring and, if necessary, changes. Those not yet on ART were re-assessed through CD4 testing every six months. The total number of visits was 8–12 in the first year, though may exceed 12 when warranted by the patient's medical condition. At enrollment, patients were invited to participate in a support group consisting of patients of similar characteristics that regularly met to receive moral support and information from peers (National AIDS and STI Control Program, 2011).

Definitions

A patient was considered a defaulter if still absent three days after missing a scheduled clinic appointment. Defaulters were described as "one-time defaulters" if they missed only one clinic appointment during the 12-month follow-up period, and as "repeat defaulters" if they missed more than one clinic appointment during the same period. Defaulter status was also described in terms of number of appointments missed, proportions of appointments missed during the 12-month follow-up period, and the cumulative number of days that elapsed between the appointment and actual visit date for all defaulted visits.

HIV program case definitions were used to describe patient outcomes as alive/active in care, dead, lost to follow-up (LTFU) or transferred. Patient tracing was done to determine true patient outcomes and avoid misclassification (National AIDS and STI Control Program, 2011).

Data analysis

Patients' age groups were dichotomized at 24 years based on the United Nations definition of young persons as those aged 15–24 years (United Nations, 2015). Chi-square statistics were used to describe patient characteristics by defaulter status. Alternating logistic regression (Generalized Estimating Equations, GEE) was used to describe factors associated with patient default over time. Cox proportional hazards were used to estimate hazard ratios associated with mortality at 12 months of follow-up. CD4 count averages were computed at each CD4 test period to visualize CD4 trends over time.

Patients with unknown outcomes (transfers out and lost to follow-up) were excluded from risk of death analyses. The total duration on care for all patients was computed from enrollment to outcome date in person-years in order to account for the time in follow-up for each patient (Bruce, Pope, & Stanistreet, 2007). Complete case analysis was adopted for missingness in the data since this was completely at random (Little, 1998). Analysis was conducted using Statistical Analysis Software (SAS) version 9.2 (SAS Institute Inc., 2012).

Ethical approval

Approval was granted by the Kenya Medical Research Institute Ethical Review Committee (SSC. No. 1525) and the US Centers for Disease Control IRB.

Results

Study cohort

Of the 1129 enrolled patients, 582 met the criteria for inclusion in the analysis (Figure 1). Patient characteristics are summarized in Table 1.

Characteristics of defaulters

Compared to non-defaulters, defaulters were significantly more likely to have attained secondary or a higher level of education (11% vs. 5%), be smokers (6% vs. 3%), and were less likely to have disclosed to both family and friends (53% vs. 60%).

Once having been a defaulter one time, a patient was significantly more likely to default at future visits (OR 1.4; 95% CI 1.12–1.77) especially the unemployed (OR 1.43; 95% CI 1.07–1.91), smokers (OR 2.22; 95% CI 1.31–3.76), and whose disclosure status was "non-specific" compared to those who disclosed to both family and friends (OR 2.17; 95% CI 1.42–3.3, p = .0003). The clinical status of patients and alcohol consumption were not associated with one-time or repeated default (Table 1). A total of 4079 appointments were scheduled for the 582 patients during the follow-up period; 367 (9%) were not kept by the defaulters during the study period.

Clinical progression

The mean increase in CD4 count at month six of follow-up was higher among the nondefaulters compared to defaulters; however, this was not statistically significant (161.1 [114.7–207.6] and 118.9 [44.4–193.4]). Further comparison beyond this was limited by limitedCD4 counts data.

Twelve-month patient mortality

Defaulters experienced significantly higher proportions of deaths compared to nondefaulters (6% vs. 2%); this difference was not significant between one-time and repeat defaulters (6% vs. 5%). A higher rate of transfers out was observed among non-defaulters and a higher rate of LTFU patients among defaulters (Figure 1).

Overall, the risk of death was significantly higher among defaulters compared to nondefaulters (HR 3.09; 95% CI 1.11–8.62), among members of support groups (HR 3.12; 95% CI 1.11–9.09) and among those who had been on ART for a shorter duration (HR 4.55; 95% CI 1.51–13.77) (data not shown).

Impact of default on year-one patient mortality

The overall mortality rate was 6.3 per 100 person years; this was lower among nondefaulters and increased significantly with the rate of patient default (p < .005) (Table 2).

Discussion

As supported by other literature, defaulters were more likely to have poorer patient outcomes. This could be attributed to missed doses of ART medication, missed opportunity

for clinical intervention, and the increased possibility of repeat default or stopping clinic attendance as suggested by higher rates of LTFU among defaulters (National AIDS and STI Control Program, 2011; Walburn, Swindells, Fisher, High, & Islam, 2012).

The default rate observed was higher than seen in urban Nairobi's Kibera slums where only one-third of patients defaulted over a three-year period (Unge et al., 2010). JOOTRH being a referral facility may have influenced this default trend. Although close to half of the patients were defaulters, they only accounted for 9% of the missed scheduled appointments. As observed in the published literature, this could be explained by the number of scheduled appointments at HIV clinics (an average of 10 annual visits), which were all kept by the non-defaulting patients and defaulters only missing a proportion of their scheduled appointments (Kunutsor et al., 2010).

An examination of patient scheduling may explain why patients with a higher level of education were more likely to default for one visit but not multiple appointments (Collazos, Asensi, Carton, & Ibarra, 2009; Lacy, Paulman, & Reuter, 2004).

The unemployed, smokers, and those with non-specific disclosure status were more likely to default multiple times verses a single time. Limited financial resources among unemployed may suggest an inability to afford transport to clinic appointments or even limited access to the food to take with ART (Bonolo et al., 2005; Falagas, Zarkadoulia, Pliatsika, & Panos, 2008). Smokers are likely to engage in other forms of drug-abuse and may have lower levels of conscientiousness (Bonolo et al., 2005; Terracciano & Costa Jr, 2004). No specific substance-use questionnaire is in place at JOOTRH, which might explain limited data on drug-abuse and hence no relationship with default (Fagan et al., 2013; World Bank, 2014). Non-specific disclosure status may mean non-disclosure of HIV status which may imply lack of family support and other behaviors related to denial of HIV status (Bofill et al., 2011). It may be that sicker patients are more likely to attend support groups, explaining their higher mortality (Shacham et al., 2008).

Our analysis was limited by missing data on TB diagnosis and other opportunistic infections, causes of death, true outcomes of untraceable patients, and a short duration of follow-up. Nonetheless, finding strategies to avoid patient default from clinic appointments may be critically important. We propose that, stable patients should have additional drug delivery options made available to facilitate medication-adherence and that HIV programs deliver targeted adherence programs that address income-related barriers, promote disclosure, discourage smoking, and educate patients on appointment-scheduling (National AIDS and STI Control Program, 2011; Unge et al., 2010; Walburn et al., 2012). Encouraging early diagnosis of HIV infection and ART uptake mean little, if patients inconsistently engage in care.

Acknowledgments

We wish to acknowledge the contribution of the health-care workers and people living with HIV at the JOOTRH HIV clinic. We also thank the Kenya Ministry of Health, including the National AIDS and STI Control Program, the JOOTRH administration and the KEMRI Director for their collaboration in this evaluation. The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention/Government of Kenya.

AIDS Care. Author manuscript; available in PMC 2016 April 06.

Funding

This publication was made possible by support from the US President's Emergency Plan for AIDS Relief (PEPFAR) through cooperative agreement no. 5U19GH000041 from the US Centers for Disease Control and Prevention (CDC), Division of Global HIV/AIDS (DGHA).

Biographies

Kimeu Muthusi currently serves as the Statistical consultant at the Food and Agriculture Organization of the United Nations (FAO), Somalia Office providing technical support in validating survey tools, developing statistical analysis plans, performing quantitative analyses and statistical abstracts on household resilience surveys conducted in Somalia. Previously, he worked as a Senior Statistician at the University of California in San-Francisco, Nairobi Office providing technical support to research officers in regard to the statistical aspects of research and program evaluation such as study design, sample size determination, power analysis, data management, analysis of data, and presentation of statistical information. Previously he was also attached to the HIV and TB Implementation Science and Services, HISS, Branch of KEMRI/CGHR as the Lead Statistician. He holds a Master of Science in Statistics, Universiteit Hasselt, Belgium, and Bachelor of Science in Mathematics and Statistics, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya. He also holds Professional – Graduate Statistician (GradStat) status at the Royal Statistical Society, United Kingdom.

Dr. Barbara Burmen currently serves as the HIV Implementation Science Coordinator at the HIV Implementation Science and Services Branch of the Kenya Medical Research Institute Center for Global Health Research. Her current duties include the use of routinely collected program data to generate scientific dissemination products with a view to ultimately improve program performance. Previously she has served as a Medical Officer in both the private and public health sector, where she was involved in the provision of HIV health services amongst others. She holds a Masters' Degree in Public Health from the University of Liverpool Laureate Online Education and a Bachelors' Degree in Medicine and Surgery from Moi University Eldoret, Kenya.

Berly Audi currently serves as the Community Activities Coordinator for the HIV Clinical Services HIV Implementation Science and Services Branch of the Kenya Medical Research Institute Center for Global Health Research. She previously worked as a Community Extension Officer at Care International. She holds a High Diploma in Community Health and Development, Great Lakes University, Kisumu, Kenya.

Anne Adega is currently a Research Officer with KEMRI/CDC HIV Implementation Science and Services program. She is involved in coordinating research studies within Operations Research section and supporting implementation science. She has previously coordinated studies in HIV Research branch of KEMRI/CDC. She holds a Master's Degree Project Planning and Management and a Bachelor's degree in Sociology both from University of Nairobi, Kenya.

of Eastern Africa.

Dr. Susan Arodi currently serves as the Medical Officer in Charge of the HIV Comprehensive Care Center at the Jaramogi Oginga Odinga Teaching and Referral Hospital. She has previously served as a Medical Officer in the Ministry of Health in various capacities. She holds a Bachelor's Degree in Medicine and Surgery, University of Nairobi.

Dr. Dennis Bii served as the Program Head of the Clinical Services Section of the HIV Implementation Science and Services Branch of KEMRI CGHR at the time of submission. The clinical services section provided HIV Care and Treatment Services at the Jaramogi Oginga Oding Teaching and Referral Hospital HIV Comprehensive Care Clinic. He previously was the Lead Clinician for the HIV PreP study at the Kenya Medical Research Institute-University of San Francisco collaboration, Kisumu Kenya. He holds a Masters' Degree in Public Health from the University of Umea International School of Public Health, Sweden and a Bachelors' Degree in Medicine and Surgery from Moi University Eldoret, Kenya.

Dr. Emily Zielinski-Gutiérrez is the current Branch Chief, Surveillance and Epidemiology Branch of CDC Division of Global HIV AIDS, Kenya. Previously she served a Behavioral Scientist at CDC Division of Vector-Borne Diseases. She holds a Doctorate in Public Health, Tulane School of Public Health and Tropical Medicine, New Orleans Louisiana; a Master's in Public Health Tulane School of Public Health and Tropical Medicine, New Orleans LA; and Bachelor of Arts, DePaul University.

References

- Alamo ST, Wagner GJ, Sunday P, Wanyenze RK, Ouma J, Kamya M. Electronic medical records and same day patient tracing improves clinic efficiency and adherence to appointments in a community based HIV/AIDS care program, in Uganda. AIDS and Behavior. 2012; 16(2):368–374. [PubMed: 21739285]
- Bofill L, Waldrop-Valverde D, Metsch L, Pereyra M, Kolber MA. Demographic and psychosocial factors associated with appointment attendance among HIV-positive outpatients. AIDS Care: Psychological and Socio- Medical Aspects of AIDS/HIV. 2011; 23(10):1219–1225.
- Bonolo P, Césarb CC, Acúrcioa FA, Ceccato MB, Páduaa CAM, Álvares J. Non-adherence among patients initiating antiretroviral therapy: A challenge for health professionals in Brazil. AIDS. 2005; 19(Suppl. 4):S5–S13. [PubMed: 16249654]
- Bruce, N.; Pope, D.; Stanistreet, D. Quantitative research methods in public health; A practical, interactive guide. England: John Wiley & Sons; 2007.
- Collazos J, Asensi V, Carton JA, Ibarra S. Grupo Españolpara el Estudio Multifactorial de la Adherencia. The influence of the patients' educational levels on socioeconomic, clinical, immunological and virological endpoints. AIDS Care. 2009; 21(4):511–519. [PubMed: 19266411]

- Fagan KJ, Irvine KM, Kumar S, Bates A, Horsfall LU, Feeney GF. Assessment of alcohol histories obtained from patients with liver disease: Opportunities to improve early intervention. Internal Medicine Journal. 2013; 43(10):1096–1102. [PubMed: 23834077]
- Falagas ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: A systematic review of the literature. Retrovirology. 2008; 5(13):1–12. [PubMed: 18177500]
- Fong RKC, Cheng AC, Vujovic O, Hoy JF. Factors associated with virological failure in a cohort of combination antiretroviral therapy-treated patients managed at a tertiary referral centre. Sexual Health. 2013; 10(5):442–447. [PubMed: 24119435]
- Kunutsor S, Walley J, Katabira E, Muchuro S, Balidawa H, Namagala E, Ikoona E. Clinic attendance formedication refills and medication adherence amongst an antiretroviral treatment cohort in Uganda: A prospective study. AIDS Research and Treatment. 2010; 2010:1–8.
- Lacy NL, Paulman A, Reuter MD. Why we don't come: Patient perceptions on no-shows. The Annals of Family Medicine. 2004; 2:541–545. [PubMed: 15576538]
- Little RJA. Test for missing completely at random for multivariate data with missing values. Journal of American Statistical Association. 1998; 83(404):1198–1202.
- Ministry of Health National AIDS and STI Control Program (NASCOP). Guidelines on use of antiretroviral drugs for treating and preventing HIV infection: A rapid advice, 2014. 2014
- National AIDS and STI Control Program. Guidelines for antiretroviral therapy in Kenya (4th). 2011 Retrieved from Nairobi, National AIDS and STI Control Program: http:// healthservices.uonbi.ac.ke/sites/default/files/centraladmin/healthservices/Kenya%20Treatment %20Guidelines %202011.pdf.
- Park WB, Choe PG, Kim SH, Jo JH, Bang JH, Kim HB. One-year adherence to clinic visits after highly active antiretroviral therapy: A predictor of clinical progress in HIV patients. Journal of Internal Medicine. 2007; 261(3):268–275. [PubMed: 17305649]
- SAS Institute Inc.. Patent No. Cary, NC: S. I. Inc.; 2012.
- Shacham E, Reece M, Ong'or WO, Omollo O, Monahan PO, Ojwang C. Characteristics of psychosocial support seeking during HIV-related treatment in Western Kenya. AIDS Patient Care STDS. 2008; 22(7):595–601. [PubMed: 18479225]
- Swash, M., editor. Hutchinson's clinical methods. 21st. London: Saunders; 2001.
- Terracciano A, Costa PT Jr. Smoking and the five-factor model of personality. Addiction. 2004; 99(4): 472–481. [PubMed: 15049747]
- Unge C, Södergård B, Marrone G, Thorson A, Lukhwaro A, Carter J. Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: A prospective cohort study. PLoS ONE. 2010; 5(10):e13613. [PubMed: 21049045]
- United Nations. Definition of Youth. 2015 Retrieved from http://www.un.org/esa/socdev/documents/ youth/fact-sheets/youth-definition.pdf.
- Walburn A, Swindells S, Fisher C, High R, Islam KM. Missed visits and decline in CD4 cell count among HIV-infected patients: A mixed method study. International Journal of Infectious Diseases. 2012; 16(11):e779–e785. [PubMed: 22902645]
- World Bank. Smoking prevalence. 2014 http://data.worldbank.org/indicator/SH.PRV.SMOK.MA.




Figure 1.

Year-one patient retention rates at the Jaramogi Oginga Odinga Teaching and Referral Hospital for patients enrolled between 2011 and 2012.

Table 1

Baseline demographic, clinical and psychosocial characteristics of HIV-infected adult patients^{*} and factors associated with rate of defaulting clinic appointment repeatedly among HIV-infected adult patients enrolled in a referral hospital in western Kenya, 2011–2012[#].

(column %) (column %) p -value] pp -value] Age group N = 582 < 24 years 66 (1) 32 (12) 1.34 (0.91-1.95); .13 >= 24 years 516 (89) 226 (88) Reference Gender N = 582				GEE m	odel
24 years 66 (11) 32 (12) 1.34 (0.91-1.95); .13 >= 24 years 516 (89) 226 (88) Reference Gender N= 582 Nather 100 (110) Reference Female 347 (60) 151 (100) (0.78-1.28); .99 Marital status Not maried 228 (41) 102 (42) 1.05 (0.81-1.37); .69 Maried 322 (59) 142 (58) Reference Employed N= 518 Vertice Reference No 229 (56) 125 (55) Reference Reference No 229 (56) 126 (55) Reference Reference No 229 (56) 126 (55) Reference Reference No 229 (56) 126 (55) Reference Reference No 229 (50) 123 (15) Reference Reference No 239 (230 (89)* 1.59 (1.12-2.26); .01 1.86 (0.91-3.82); .09 Above primary 44 (8) 28 (11) Reference Reference Starge III set Primary 187 (33) 89 (55) Reference Reference Starge III set Primary 187	Characteristic				
> 24 years516 (8)226 (8)ReferenceGenderN= 582Male235 (40)107 (41)ReferenceFemale347 (60)151 (59)1.00 (0.78-1.28); 99Marital statusN= 550Not married228 (41)102 (42)1.05 (0.81-1.37); .69Married228 (41)102 (42)1.05 (0.81-1.37); .69Married228 (55)124 (58)ReferenceEmployedN= 518Yes289 (56)125 (55)ReferenceNo229 (44)102 (45)1.33 (1.03-1.73); .031.62 (1.03-2.56); .04Education levelN= 582Primary or less538 (92) $_{230}$ (89)*1.59 (1.12-2.26); .011.86 (0.91-3.82); .09Above primary44 (8)28 (11)ReferenceReferenceEntry pointN= 573Within facility387 (57)164 (65)ReferenceStage I & H329 (57)147 (59)ReferenceReferenceStage I & KI329 (57)147 (59)ReferenceStage I & KI329 (57)147 (59)Reference;Stage II & KIV244 (43)104 (41)1.26 (0.98-1.62); .071.22 (0.82-1.81); .33CD4 category ² $N= 567$ Yes76 (13)32 (11)Reference;No501 (87)225 (89)0.30 (0.21-1.11); .14> 350 cells/mm³422 (75)31 (12)1.05 (0.71-1.54); .81	Age group	N= 582			
Gender N= 582 Male 235 (4) 107 (41) Reference Female 347 (60) 151 (59) 1.00 (0.78-1.28); .99 Marital status N= 550 Not married 228 (41) 102 (42) 1.05 (0.81-1.37); .69 Married 322 (59) 142 (58) Reference Employed N= 518 V V Yes 229 (44) 102 (45) 1.33 (1.03-1.73); .03 1.62 (1.03-2.56); .04 Education level N= 582 V V No 229 (44) 102 (45) 1.33 (1.03-1.73); .03 1.62 (1.03-2.56); .04 Education level N= 582 V V No 1.86 (0.91-3.82); .09 Above primary 44 (8) 28 (11) Reference Reference Entry point N= 572 V No No No No No (20, 62) Reference Reference Stage I& II 326 (67) 146 (65) Reference Reference Reference Stage II (1.13) No	< 24 years	66 (11)	32 (12)	1.34 (0.91–1.95); .13	
Male235 (4)107 (4)ReferenceFemale347 (60)151 (59)1.00 (0.78-1.28); 99Marital status $N=550$ Not married228 (41)102 (42)1.05 (0.81-1.37); 69Married322 (59)142 (58)ReferenceEmployed $N=518$ Yes289 (50)125 (55)ReferenceNo229 (44)102 (45)1.31 (0.31-173); 031.62 (1.03-2.56); 04Education level $N=582$ Primary or less538 (92) $2_{20} (89)^{*}$ 1.59 (1.12-2.26); 011.86 (0.91-3.82); 09Above primary44 (8)28 (11)ReferenceReferenceEntry point $N=572$ Within facility385 (67)164 (65)ReferenceReferenceOutside facility187 (33)89 (35)1.01 (0.78-1.30); .95WHO stage $N=573$ </td <td>>= 24 years</td> <td>516 (89)</td> <td>226 (88)</td> <td>Reference</td> <td></td>	>= 24 years	516 (89)	226 (88)	Reference	
Female Female347 (60) 151 (59)1.00 (0.78–1.28); 99Marital statusN=550Not married228 (41)102 (42)1.05 (0.81–1.37); 69Married322 (59)142 (58)ReferenceEmployedN=518Yes289 (56)125 (55)ReferenceNo229 (44)102 (45)1.33 (1.03–1.73); 031.62 (1.03–2.56); 04Education levelN=582Primary or less538 (92) $2_{30} (89)^*$ 1.59 (1.12–2.26); 011.86 (0.91–3.82); 09Above primary44 (8)28 (11)ReferenceReferenceEntry pointN=572Within facility385 (67)164 (65)ReferenceOutside facility187 (33)89 (35)1.01 (0.78–1.30); 95WHO stageN=573Stage 1 & II329 (57)147 (59)ReferenceReferenceStage 1 & II329 (57)147 (59)Reference;Stage 1 & IV244 (43)104 (41)1.26 (0.98–1.62); 071.22 (0.82–1.81); .33CD4 category *N=564Yes76 (13)32 (11)Reference;No501 (87)225 (89)0.93 (0.62–1.41); .75Disclosure *N=582Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71–1.54); .81Disclosure *N=50 <td>Gender</td> <td>N= 582</td> <td></td> <td></td> <td></td>	Gender	N= 582			
Marital statusN = 550Not married228 (41)102 (42)1.05 (0.81–1.37); .69Married322 (59)142 (58)ReferenceEmployedN = 518Yes289 (56)125 (55)ReferenceNo229 (44)102 (45)1.33 (1.03–1.73); .031.62 (1.03–2.56); .04Education levelN = 582Primary or less538 (92) $230 (89)^{*}$ 1.59 (1.12–2.26); .011.86 (0.91–3.82); .09Above primary44 (8)28 (11)ReferenceReferenceEntry pointN = 572Within facility38 (67)164 (65)ReferenceReferenceOutside facility187 (33)89 (35)1.01 (0.98–1.30); .95WHO stageN = 573 </td <td>Male</td> <td>235 (40)</td> <td>107 (41)</td> <td>Reference</td> <td></td>	Male	235 (40)	107 (41)	Reference	
Not married228 (41)102 (42)1.05 (0.81-1.37); .69Married322 (59)142 (58)ReferenceEmployed $N = 518$ Yes289 (56)125 (55)ReferenceReferenceNo229 (44)102 (45)1.33 (1.03-1.73); .031.62 (1.03-2.56); .04Education level $N = 582$ Primary or less538 (92) $230 (89)^{*}$ 1.59 (1.12-2.26); .011.86 (0.91-3.82); .09Above primary44 (8)28 (11)ReferenceReferenceEntry point $N = 572$ Within facility385 (67)164 (65)ReferenceReferenceOutside facility187 (33)89 (35)1.01 (0.78-1.30); .95WHO stage $N = 573$ Stage I & II329 (57)147 (59)ReferenceReferenceStage I & II329 (57)147 (59)ReferenceStage I & II329 (57)184 (74)0.74 (0.49-1.11); .14 > 350 cells/mm ³ 422 (75)184 (74)0.74 (0.49-1.11); .14 > 350 cells/mm ³ 142 (25)66 (26)Reference;No50 (87)225 (89)0.93 (0.62-1.41); .75Disclosure s ⁴ $N = 572$ Yes76 (13)32 (11)Reference;No50 (87)225 (89)0.93 (0.62-1.41); .75Disclosure s ⁴ $N = 510$ Yes510 (88)227 (88)Reference;	Female	347 (60)	151 (59)	1.00 (0.78–1.28); .99	
Married322 (59)142 (58)ReferenceEmployed $N = 518$ Yes289 (56)125 (55)ReferenceReferenceNo229 (44)102 (45)1.33 (1.03-1.73); .031.62 (1.03-2.56); .04Education level $N = 582$ 1.59 (1.12-2.26); .011.86 (0.91-3.82); .09Above primary44 (8)28 (11)ReferenceReferenceEntry point $N = 572$ 1.64 (65)ReferenceOutside facility187 (33)89 (35)1.01 (0.78-1.30); .95Within facility385 (67)164 (65)ReferenceReferenceOutside facility187 (33)89 (35)1.01 (0.78-1.30); .95WHO stage $N = 573$ </td <td>Marital status</td> <td>N= 550</td> <td></td> <td></td> <td></td>	Marital status	N= 550			
LemployedN = 518KefferenceReferenceYes289 (56)125 (55)ReferenceReferenceNo229 (44)102 (45)1.33 (1.03–1.73); .031.62 (1.03–2.56); .04Education levelN=582Primary or less538 (92) $2_{30} (89)^*$ 1.59 (1.12–2.26); .011.86 (0.91–3.82); .09Above primary44 (8)28 (11)ReferenceReferenceEntry pointN=572Within facility385 (67)164 (65)ReferenceOutside facility187 (33)89 (35)1.01 (0.78–1.30); .95WHO stageN=573Stage I & II329 (57)147 (59)ReferenceReferenceStage II & IV244 (43)104 (41)1.26 (0.98–1.62); .071.22 (0.82–1.81); .33CD4 category //N=564 <abr></abr> > a 500 cells/mm ³ 422 (75)184 (74)0.74 (0.49–1.11); .14>=350 cells/mm ³ 142 (25)66 (26)Reference;Member of a support group //N=577Yes76 (13)32 (11)ReferenceNo501 (87)225 (89)0.93 (0.62–1.41); .75Disclosure fN=578Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71–1.54); .81Disclosure fN=510Yes510 (89) $27 (16)^*$ 1.38 (0.96–1.99); .081.13 (0.50–2.53); .77 </td <td>Not married</td> <td>228 (41)</td> <td>102 (42)</td> <td>1.05 (0.81–1.37); .69</td> <td></td>	Not married	228 (41)	102 (42)	1.05 (0.81–1.37); .69	
Yes289 (56)125 (55)ReferenceReferenceNo229 (44)102 (45)1.33 (1.03-1.73); .031.62 (1.03-2.56); .04Education level $N = 582$ Primary or less538 (92) $_{230 (89)}^*$ 1.59 (1.12-2.26); .011.86 (0.91-3.82); .09Above primary44 (8)28 (11)ReferenceReferenceEntry point $N = 572$ Within facility385 (67)164 (65)ReferenceOutside facility187 (33)89 (35)1.01 (0.78-1.30); .95WHO stage $N = 573$ Stage II & II329 (57)147 (59)ReferenceReferenceStage II & IV244 (43)104 (41)1.26 (0.98-1.62); .071.22 (0.82-1.81); .33CD4 category I $N = 564$ < 350 cells/mm ³ 142 (25)66 (26)Reference;Member of a support group I $N = 577$ Yes76 (13)32 (11)Reference;No501 (87)225 (89)0.93 (0.62-1.41); .75Disclosure I $N = 582$ Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71-1.54); .81Disclosed to who $N = 510$ Yes94 (18) $37 (16)^*$ 1.38 (0.96-1.99); .081.13 (0.50-2.53); .77	Married	322 (59)	142 (58)	Reference	
No229 (4)102 (45)1.33 (1.03-1.73); .031.62 (1.03-2.56); .04Education level $N = 582$ Primary or less538 (92) $230 (89)^*$ 1.59 (1.12-2.26); .011.86 (0.91-3.82); .09Above primary44 (8)28 (11)ReferenceReferenceEntry point $N = 572$ Within facility385 (67)164 (65)ReferenceOutside facility187 (33)89 (35)1.01 (0.78-1.30); .95WHO stage $N = 573$ Stage I & II329 (57)147 (59)ReferenceReferenceStage II & IV244 (43)104 (41)1.26 (0.98-1.62); .071.22 (0.82-1.81); .33CD4 category $N = 564$ < 350 cells/mm ³ 422 (75)184 (74)0.74 (0.49-1.11); .14>= 350 cells/mm ³ 142 (25)66 (26)Reference;Member of a support group $N = 577$ Yes76 (13)32 (11)Reference;No501 (87)225 (89)0.93 (0.62-1.41); .75Disclosure $N = 582$ Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71-1.54); .81Disclosed to who $N = 510$ Faring only94 (18) 37 (16) *1.38 (0.96-1.99); .081.13 (0.50-2.53); .77	Employed	N= 518			
Education level $N = 582$ Primary or less $538 (92)$ $230 (89)^*$ $1.59 (1.12-2.26); .01$ $1.86 (0.91-3.82); .09$ Above primary $44 (8)$ $28 (11)$ ReferenceReferenceEntry point $N = 572$ Within facility $385 (67)$ $164 (65)$ ReferenceOutside facility $187 (33)$ $89 (35)$ $1.01 (0.78-1.30); .95$ WHO stage $N = 573$ Stage I & II $329 (57)$ $147 (59)$ ReferenceReferenceStage II & IV $244 (43)$ $104 (41)$ $1.26 (0.98-1.62); .07$ $1.22 (0.82-1.81); .33$ CD4 category f $N = 564$ < $350 cells/mm^3$ $422 (75)$ $184 (74)$ $0.74 (0.49-1.11); .14$ >= $350 cells/mm^3$ $142 (25)$ $66 (26)$ Reference;Member of a support group f $N = 577$ Yes $76 (13)$ $32 (11)$ Reference;No $501 (87)$ $225 (89)$ $0.93 (0.62-1.41); .75$ Disclosure f $N = 582$ Yes $510 (88)$ $227 (88)$ Reference;No $72 (12)$ $31 (12)$ $1.05 (0.71-1.54); .81$ Disclosed to who $N = 510$ $1.38 (0.96-1.99); .08$ $1.13 (0.50-2.53); .77$	Yes	289 (56)	125 (55)	Reference	Reference
Primary or less $538 (92)$ ${230 (89)}^*$ $1.59 (1.12-2.26); .01$ $1.86 (0.91-3.82); .09$ Above primary $44 (8)$ $28 (11)$ ReferenceReferenceEntry point $N = 572$ $N = 572$ $N = 573$ $N = 573$ Within facility $187 (33)$ $89 (35)$ $1.01 (0.78-1.30); .95$ $N = 573$ Stage I & II $329 (57)$ $147 (59)$ ReferenceReferenceStage I & II $329 (57)$ $147 (59)$ ReferenceReferenceStage I & II $329 (57)$ $147 (59)$ ReferenceReferenceStage III & IV $244 (43)$ $104 (41)$ $1.26 (0.98-1.62); .07$ $1.22 (0.82-1.81); .33$ CD4 category	No	229 (44)	102 (45)	1.33 (1.03–1.73); .03	1.62 (1.03–2.56); .04
Above primary44 (8)28 (11)ReferenceReferenceEntry point $N = 572$ Within facility385 (67)164 (65)ReferenceOutside facility187 (33)89 (35)1.01 (0.78–1.30); .95WHO stage $N = 573$ Stage I & II329 (57)147 (59)ReferenceStage III & IV244 (43)104 (41)1.26 (0.98–1.62); .071.22 (0.82–1.81); .33CD4 category $N = 564$ < 350 cells/mm ³ 422 (75)184 (74)0.74 (0.49–1.11); .14>= 350 cells/mm ³ 142 (25)66 (26)Reference;Member of a support group F $N = 577$ Yes76 (13)32 (11)ReferenceNo501 (87)225 (89)0.93 (0.62–1.41); .75Disclosure t^* $N = 582$ Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71–1.54); .81Disclosed to who $N = 510$ Yes94 (18) 37 (16) t^* 1.38 (0.96–1.99); .081.13 (0.50–2.53); .77	Education level	N= 582			
Entry point $N = 572$ Within facility385 (67)164 (65)ReferenceOutside facility187 (33)89 (35)1.01 (0.78–1.30); .95WHO stage $N = 573$ $N = 573$ Stage I & II329 (57)147 (59)ReferenceStage II & IV244 (43)104 (41)1.26 (0.98–1.62); .071.22 (0.82–1.81); .33CD4 category $N = 564$ $N = 564$ $N = 350$ cells/mm ³ 422 (75)184 (74)0.74 (0.49–1.11); .14>= 350 cells/mm ³ 142 (25)66 (26)Reference; $N = 577$ Yes76 (13)32 (11)ReferenceNo501 (87)225 (89)0.93 (0.62–1.41); .75Disclosure $\frac{2}{7}$ $N = 582$ $N = 582$ Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71–1.54); .81Disclosed to who $N = 510$ $N = 510$ Weing only94 (18) 37 (16) *1.38 (0.96–1.99); .081.13 (0.50–2.53); .77	Primary or less	538 (92)	230 (89)*	1.59 (1.12–2.26); .01	1.86 (0.91–3.82); .09
With With facility385 (67)164 (65)ReferenceOutside facility187 (33)89 (35)1.01 (0.78–1.30); .95WHO stage $N = 573$ Stage I & II329 (57)147 (59)ReferenceStage II & IV244 (43)104 (41)1.26 (0.98–1.62); .071.22 (0.82–1.81); .33CD4 category V $N = 564$ < 350 cells/mm ³ 422 (75)184 (74)0.74 (0.49–1.11); .14>= 350 cells/mm ³ 142 (25)66 (26)Reference;Member of a support group V $N = 577$ Yes76 (13)32 (11)ReferenceNo501 (87)225 (89)0.93 (0.62–1.41); .75Disclosure $\frac{1}{2}$ $N = 582$ Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71–1.54); .81Disclosed to who $N = 510$ Family only94 (18) 37 (16) *1.38 (0.96–1.99); .081.13 (0.50–2.53); .77	Above primary	44 (8)	28 (11)	Reference	Reference
Outside facility187 (3)89 (35)1.01 (0.78–1.30); .95WHO stage $N = 573$	Entry point	N= 572			
WHO stage $N = 573$ Stage I & II329 (57)147 (59)ReferenceReferenceStage III & IV244 (43)104 (41)1.26 (0.98–1.62); .071.22 (0.82–1.81); .33CD4 category $N = 564$ < 350 cells/mm ³ 422 (75)184 (74)0.74 (0.49–1.11); .14>= 350 cells/mm ³ 142 (25)66 (26)Reference;Member of a support group $N = 577$ Yes76 (13)32 (11)ReferenceNo501 (87)225 (89)0.93 (0.62–1.41); .75Disclosure $N = 582$ Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71–1.54); .81Disclosed to who $N = 510$ Family only94 (18)37 (16) *1.38 (0.96–1.99); .081.13 (0.50–2.53); .77	Within facility	385 (67)	164 (65)	Reference	
Stage I & II329 (57)147 (59)ReferenceReferenceStage II & IV244 (43)104 (41)1.26 (0.98–1.62); .071.22 (0.82–1.81); .33CD4 category $\sqrt[7]$ N= 564< 350 cells/mm ³ 422 (75)184 (74)0.74 (0.49–1.11); .14>= 350 cells/mm ³ 142 (25)66 (26)Reference;Member of a support group \checkmark N= 577Yes76 (13)32 (11)ReferenceNo501 (87)225 (89)0.93 (0.62–1.41); .75Disclosure \checkmark N= 582Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71–1.54); .81Disclosed to whoN= 510Family only94 (18)37 (16) *1.38 (0.96–1.99); .081.13 (0.50–2.53); .77	Outside facility	187 (33)	89 (35)	1.01 (0.78–1.30); .95	
Stage III & IV $244 (43)$ $104 (41)$ $1.26 (0.98-1.62); .07$ $1.22 (0.82-1.81); .33$ CD4 category $N = 564$ < 350 cells/mm ³ $422 (75)$ $184 (74)$ $0.74 (0.49-1.11); .14$ >= 350 cells/mm ³ $142 (25)$ $66 (26)$ Reference;Member of a support group $N = 577$ $N = 577$ Yes $76 (13)$ $32 (11)$ ReferenceNo $501 (87)$ $225 (89)$ $0.93 (0.62-1.41); .75$ Disclosure $N = 582$ $N = 582$ Yes $510 (88)$ $227 (88)$ Reference;No $72 (12)$ $31 (12)$ $1.05 (0.71-1.54); .81$ Disclosed to who $N = 510$ $N = 510$ Family only $94 (18)$ $37 (16)^*$ $1.38 (0.96-1.99); .08$ $1.13 (0.50-2.53); .77$	WHO stage	N= 573			
CD4 category	Stage I & II	329 (57)	147 (59)	Reference	Reference
< 350 cells/mm³422 (75)184 (74) $0.74 (0.49-1.11); .14$ >= 350 cells/mm³142 (25)66 (26)Reference;Member of a support group¥ $N=577$	Stage III & IV	244 (43)	104 (41)	1.26 (0.98–1.62); .07	1.22 (0.82–1.81); .33
>= 350 cells/mm³142 (25)66 (26)Reference;Member of a support group¥ $N=577$	CD4 category ¶	N= 564			
Member of a support group \checkmark N= 577Yes76 (13)32 (11)ReferenceNo501 (87)225 (89)0.93 (0.62–1.41); .75Disclosure \ddagger N= 582Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71–1.54); .81Disclosed to whoN= 510Family only94 (18)37 (16)*1.38 (0.96–1.99); .081.13 (0.50–2.53); .77	< 350 cells/mm ³	422 (75)	184 (74)	0.74 (0.49–1.11); .14	
Yes76 (13)32 (11)ReferenceNo501 (87)225 (89) $0.93 (0.62-1.41); .75$ Disclosure $\stackrel{\ddagger}{}$ $N = 582$ Yes510 (88)227 (88)Reference;No72 (12)31 (12) $1.05 (0.71-1.54); .81$ Disclosed to who $N = 510$ $N = 510$ Family only94 (18) $37 (16)^{*}$ $1.38 (0.96-1.99); .08$ $1.13 (0.50-2.53); .77$	>= 350 cells/mm ³	142 (25)	66 (26)	Reference;	
Yes76 (13)32 (11)ReferenceNo501 (87)225 (89) $0.93 (0.62-1.41); .75$ Disclosure \ddagger $N=582$ Yes510 (88)227 (88)Reference;No72 (12)31 (12) $1.05 (0.71-1.54); .81$ Disclosed to who $N=510$ Family only94 (18) $37 (16)^*$ $1.38 (0.96-1.99); .08$ $1.13 (0.50-2.53); .77$	Member of a support group \mathcal{F}	N= 577			
No501 (87)225 (89) $0.93 (0.62-1.41); .75$ Disclosure \ddagger $N=582$ Keference;Yes510 (88)227 (88)Reference;No72 (12)31 (12) $1.05 (0.71-1.54); .81$ Disclosed to who $N=510$ Interval 1.13 (0.50-2.53); .77Family only94 (18) $37 (16)^*$ $1.38 (0.96-1.99); .08$ $1.13 (0.50-2.53); .77$		76 (13)	32 (11)	Reference	
Disclosure \ddagger N= 582Yes510 (88)227 (88)Reference;No72 (12)31 (12)1.05 (0.71-1.54); .81Disclosed to whoN= 510Family only94 (18)37 (16) *1.38 (0.96-1.99); .081.13 (0.50-2.53); .77	No		225 (89)	0.93 (0.62–1.41); .75	
Yes $510 (88)$ $227 (88)$ Reference;No $72 (12)$ $31 (12)$ $1.05 (0.71-1.54); .81$ Disclosed to who $N=510$ Image: Simple colspan="3">Image: Simple colspan="3">Reference;No $72 (12)$ $31 (12)$ $1.05 (0.71-1.54); .81$ Disclosed to who $N=510$ Image: Simple colspan="3">Image: Simple colspan="3"Family only $94 (18)$ $37 (16)^*$ $1.38 (0.96-1.99); .08$ $1.13 (0.50-2.53); .77$	Disclosure			· · · ·	
No72 (12)31 (12) $1.05 (0.71-1.54); .81$ Disclosed to who $N=510$ Family only94 (18) $37 (16)^*$ $1.38 (0.96-1.99); .08$ $1.13 (0.50-2.53); .77$		510 (88)	227 (88)	Reference:	
Disclosed to who $N = 510$ Family only94 (18)37 (16)*1.38 (0.96–1.99); .081.13 (0.50–2.53); .77		. ,		,	
Family only 94 (18) 37 (16)* 1.38 (0.96–1.99); .08 1.13 (0.50–2.53); .77			21 (12)	100 (011 101), 101	
5, (10)			37 (16)*	1.38 (0.96–1.99); .08	1.13 (0.50–2.53): .77
	Friends only	26 (5)	37 (16) 11 (5)	1.51 (0.76–2.97); .24	0.96 (0.29–3.20); .96

AIDS Care. Author manuscript; available in PMC 2016 April 06.

			GEE m	odel
Characteristic	Total = 582, N (column %)	Defaulter, N (column %)	Univariate analysis [OR (95%CI); <i>p</i> -value]	Multivariate analysis [OR (95%CI); <i>p</i> -value]
Family & friends	288 (57)	120 (53)	Reference	Reference
Not specified	102 (20)	59 (26)	1.90 (1.41–2.57); <.01	2.30 (1.45-3.65); <.01
Smoking	N= 582			
Yes	24 (4)	16 (6)*	1.91 (1.09–3.35); .02	3.15(1.60-6.21); <.01
No	558 (96)	242 (94)	Reference	Reference
Alcohol	N= 582			
Yes	62 (11)	30 (11)	1.16 (0.77–1.75); .47	
No	520 (89)	228 (89)	Reference	

* Chi-square statistics used to compare characteristics of defaulters to non-defaulters.

Alternating logistic regression used to determine risk factors for repeat default among HIV-infected patients.

 $\[Member McD4\]$ counts within one month of enrollment were available for 564 patients (314 non-defaulters, 250 defaulters).

 $\stackrel{\textit{}}{}_{\text{Enrollment in a support group within one month of enrollment in care.}$

 $\overset{\sharp}{}$ Disclosure status within one month of enrollment in care.

[#]Education level strongly correlated to "disclosed to who" (correlation = -.04, p = .018) hence not significant in the multivariate model. We conducted multicolinearity test after we found it was significant in the univariate analysis and not in the multivariate analysis.

\rightarrow
<u> </u>
-
~
0
-
_
<
\leq
≦a
Mar
Man
Manu
Ē
7
Ē
IUSC
SDI
nuscri
IUSC

Author Manuscript

#((
330
= 53
JOOTRH, 2011–2012 [*] (N =
*
012
-50
1
201
5
TRH
Ē
8
t J
s a
nt
tie
pa
ed
ect
nf
V-infec
Ħ
ЧP
lle
ILO
eı
nong newly eni
lev
50
on
Ш
No.
ality an
nti
ŭ
Э
ō
ear-one mortal
Уć
on
ments on yea
len
utu
oir
dd
ca
ΞŪ.
cli
to
ice
en
heı
adl
of
ċ
pa
Im

	Number of patients	Number Of deaths	Number of Number of Total duration of follow-up Occurrence rate of event per 100 patients deaths in years person years (95% CI)	Occurrence rate of event per 100 person years (95% CI)	Unadjusted HK (95% CI)	<i>p</i> -value
Total	530	19	302.3	6.3 (3.6–9.6)		
Cumulative elapsed time (days)	l time (days)					
None	313	7	218.2	3.2 (1.3–6.5)	Reference	I
4–60 days	177	7	63.7	11.0 (4.5–21.2)	4.50 (1.53–13.20)	.006
60+ days	40	5	20.5	24.4 (8.2–47.2)	6.75 (1.96–23.18)	.002
Number of defaulted appointments	d appointments					
Zero	313	L	218.2	3.2 (1.3–6.5)	Reference	I
One	155	8	50.1	16.0 (7.2–29.1)	6.74 (2.38–19.13)	.0003
Two or more	62	4	34.1	11.7 (3.3–27.4)	3.21 (0.82–12.57)	.094
Proportion of appointments missed	intments missed					
Zero	313	L	218.2	3.2 (1.3–6.5)	Reference	I
0-25%	165	L	59.9	11.7 (4.7–22.6)	4.14 (1.35–12.65)	.013
>25%	52	5	24.3	20.6 (7.1–42.2)	7.13 (2.24–22.70)	.001

AIDS Care. Author manuscript; available in PMC 2016 April 06.

#Incidence rates of death among each group were computed as the ratio between number of deaths and total follow-up time among patients in each group.